A214390 Stock Overview
Manufactures and sells active pharmaceutical ingredients and finished drugs in South Korea and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Kyongbo Pharmaceutical Co., Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩5,620.00 |
| 52 Week High | ₩8,050.00 |
| 52 Week Low | ₩5,300.00 |
| Beta | 1.2 |
| 1 Month Change | -20.85% |
| 3 Month Change | n/a |
| 1 Year Change | -27.48% |
| 3 Year Change | -38.51% |
| 5 Year Change | -6.18% |
| Change since IPO | -83.59% |
Recent News & Updates
Recent updates
Kyongbo Pharmaceutical Co., Ltd (KRX:214390) Investors Are Less Pessimistic Than Expected
Feb 19
Kyongbo Pharmaceutical (KRX:214390) Has A Somewhat Strained Balance Sheet
Mar 09What Type Of Shareholders Own The Most Number of Kyongbo Pharmaceutical Co., Ltd (KRX:214390) Shares?
Feb 02Kyongbo Pharmaceutical Co., Ltd's (KRX:214390) Financials Are Too Obscure To Link With Current Share Price Momentum: What's In Store For the Stock?
Jan 12Did You Miss Kyongbo Pharmaceutical's (KRX:214390) Impressive 107% Share Price Gain?
Dec 25Is Kyongbo Pharmaceutical (KRX:214390) A Risky Investment?
Dec 08
Does Kyongbo Pharmaceutical's (KRX:214390) Statutory Profit Adequately Reflect Its Underlying Profit?
Nov 18Shareholder Returns
| A214390 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | -9.2% | -2.1% | 2.2% |
| 1Y | -27.5% | -4.8% | -5.7% |
Return vs Industry: A214390 underperformed the KR Pharmaceuticals industry which returned -4.8% over the past year.
Return vs Market: A214390 underperformed the KR Market which returned -5.7% over the past year.
Price Volatility
| A214390 volatility | |
|---|---|
| A214390 Average Weekly Movement | 8.5% |
| Pharmaceuticals Industry Average Movement | 4.0% |
| Market Average Movement | 5.5% |
| 10% most volatile stocks in KR Market | 11.8% |
| 10% least volatile stocks in KR Market | 2.6% |
Stable Share Price: A214390's share price has been volatile over the past 3 months compared to the KR market.
Volatility Over Time: Insufficient data to determine A214390's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | n/a | Tae-Young Kim | www.kbpharma.co.kr |
Kyongbo Pharmaceutical Co., Ltd manufactures and sells active pharmaceutical ingredients and finished drugs in South Korea and internationally. The company offers general, cephalosporins, and anti-cancer APIs; prescription drugs, including anesthetic, cardiovascular, digestive, and antibiotics; and OTC drugs. It also provides medical devices, including portable X-ray machine and ultrasonic diagnostic equipment; and extraporeal shockwave therapy and temperature control PROBE.
Kyongbo Pharmaceutical Co., Ltd Fundamentals Summary
| A214390 fundamental statistics | |
|---|---|
| Market cap | ₩134.36b |
| Earnings (TTM) | ₩4.92b |
| Revenue (TTM) | ₩240.51b |
27.3x
P/E Ratio0.6x
P/S RatioIs A214390 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A214390 income statement (TTM) | |
|---|---|
| Revenue | ₩240.51b |
| Cost of Revenue | ₩163.51b |
| Gross Profit | ₩77.00b |
| Other Expenses | ₩72.07b |
| Earnings | ₩4.92b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 206.00 |
| Gross Margin | 32.01% |
| Net Profit Margin | 2.05% |
| Debt/Equity Ratio | 60.4% |
How did A214390 perform over the long term?
See historical performance and comparisonDividends
0.9%
Current Dividend Yieldn/a
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/23 03:03 |
| End of Day Share Price | 2025/03/21 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Kyongbo Pharmaceutical Co., Ltd is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kyung Jun Moon | MERITZ Securities Co., Ltd. |
| Seung-Ho Lee | NH Investment & Securities Co., Ltd. |